Combination therapy for disorders of the lower urinary tract with A2d ligands and NSAIDs.

Ligand of α2δ subunit calcium channel (A2d) selected from gabapentin, pregabalin, (1R, 5R, 6S) -6-aminomethyl-6-carboximetilbiciclo [3.2.0] heptane, 3- (1-aminometilciclohexilmetil) -4H -1, 2, 4oxadiazol-5-one, 5- (1-aminometilciclohexilmetil) -1H-tetrazole, (3S, 4S) - (1-aminomethyl-1-carboxymethyl-3, 4dimetilciclopentano, (1α, 3α, 5α) - (3-aminomethyl-3-carboximetilbiciclo [3.2.0] heptane, (3S, 5R) 5-methyloctanoic -3aminometil-, (3S, 5R) -3-amino-5-methyl-heptanoic acid, (3S, 5R) - 3-amino-5metiloctanoico, (3S, 5R) -3-amino-5-methylnonanoic, (2S, 4S) -4- (3-chlorophenoxy) -proline or (2S, 4S) -4- (3-fluorobenzyl) -proline or a mixture of two or more thereof, for use in the treatment of urinary incontinence in a patient suffering from a disorder of the lower urinary tract with prior, simultaneous or subsequent administration of an antiinflammatory drug drug (NSAID) .